Skip to content
Search

Latest Stories

Over half a million dementia cases could go undiagnosed by 2040, study predicts

Over half a million dementia cases could go undiagnosed by 2040, study predicts

Currently, an estimated 850,000 people are living with dementia in the UK, with 315,000 undiagnosed cases

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted.


The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is “no progress in improving diagnosis rates.”

At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed.

Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations.  Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.

Richard Sloggett, programme director at the Future Health Research Centre and report author said: “Progress is being made on increasing dementia diagnosis rates, but this research shows that business as usual will not deliver what patients need.”

“The expected significant increase in dementia cases means that without investment in increased diagnostic capacity and capability more and more people will have undiagnosed dementia and be unable to access the treatment and care that they need.

“The publication of system readiness plans for new treatments coupled with new diagnosis targets backed up with investment in diagnostics and incentives should be a priority for each government of the four UK nations,” he added.

The research explored three different scenarios for the trajectory of dementia diagnosis rates up to 2040.

If the diagnosis rates in 2040 were to remain unchanged from present levels across all four UK nations, it's projected that over 565,000 individuals – nearly a quarter of a million more than today – would have dementia without a diagnosis.

If all UK nations were to achieve the two-thirds target set in England, there would be a smaller but still significant increase of 175,000 undiagnosed cases, bringing the total to 490,000 cases.

Only when all four nations significantly boost diagnosis rates to 80 per cent, there would be a decrease in the overall number of undiagnosed individuals with dementia by 2040. However, even in this scenario, nearly 300,000 cases of undiagnosed dementia would persist, the study predicted.

To tackle low diagnosis rates, the report suggested setting of new, more ambitious dementia diagnosis targets, along with the introduction of financial incentives to support their delivery.

Laura Steele, president and general manager of Lilly UK, also exphasised the need to improve diagnostic capabilities to “tackle inequalities in diagnosis rates and ensure people can access the right care and support.”

The study underscored the importance of timely and accurate diagnosis to enable dementia patients to access the care and support they need, as well as gain benefit from the potential arrival of new treatments.

More For You

NHS to roll out RSV vaccinations across 200 pharmacies in 2025/26

NHS England aims to ensure that everyone aged 75 to 79 years old is offered RSV vaccination by 31 August 2025.

Photo credit: gettyimages

RSV vaccination pilot to expand to 200 pharmacies in 2025/26

As part of its public health functions for 2025/26, NHS England plans to expand the Respiratory Syncytial Virus (RSV) immunisation programme to include up to 200 community pharmacies in targeted areas.

This follows the launch of an early adopter initiative in September 2024, where 50 community pharmacy sites in the East of England were commissioned to offer RSV vaccinations.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less